Abstract
Valproate-induced Fanconi Syndrome (VFS) is a rare complication of this therapy that has been previously described only in children with epilepsy. We report the first known case of an adult with VFS. Metabolic derangements lead patients to present with fatigue, confusion, weakness, and even bone fractures. Identification and discontinuation of the offending agent is the treatment of choice and helps confirm the diagnosis. This case highlights the importance of surveillance for metabolic derangements among patients on long term therapy with this commonly prescribed medication.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lenoir GR, Perignon JL, Gubler MC, et al. Valproic acid: a possible cause of proximal tubular renal syndrome. J Pediatr. 1981;98(3):503–4.
Hawkins E, Brewer E. Renal toxicity induced by valproic acid (Depakene). Pediatr Pathol. 1993;13(6):863–8.
Lande MB, Kim MS, Bartlett C, et al. Reversible Fanconi syndrome associated with valproate therapy. J Pediatr. 1993;123(2):320–2.
Smith GC, Balfe JW, Kooh SW. Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant. 1995;10(4):543–5.
Altunbasak S, Yildizas D, Anarat A, et al. Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatr Nephrol. 2001;16(3):256–9.
Yoshikawa H, Watanabe T, Abe T. Fanconi syndrome caused by sodium valproate: report of three severely disabled children. Eur J Paediatr Neurol. 2002;6(3):165–7.
Zaki EL, Springate JE. Renal injury from valproic acid: case report and literature review. Pediatr Neurol. 2002;27(4):318–9.
Knorr M, Schaper J, Harjes M, et al. Fanconi syndrome caused by antiepileptic therapy with valproic Acid. Epilepsia. 2004;45(7):868–71.
Jaffe SL, Sanford M. Valproate-induced proximal renal tubular dysfunction: clinically relevant in the severely disabled epileptic population. Epilepsia. 2005;46(4):599–600.
Watanabe T, Yoshikawa H, Yamazaki S, et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol. 2005;20(6):814–7.
Ono H. A severe disabled case of incomplete Fanconi syndrome after discontinuation of carnitine supplementation during valproate sodium therapy. No To Hattatsu. 2007;39(3):226–7.
Clarke BL, Wynne AG, Wilson DM, et al. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf). 1995;43(4):479–90.
Thirumurugan A, Thewles A, Gilbert RD, et al. Urinary L-lactate excretion is increased in renal Fanconi syndrome. Nephrol Dial Transplant. 2004;19(7):1767–73.
Coude FX, Grimber G, Pelet A, et al. Action of the antiepileptic drug, valproic acid, on fatty acid oxidation in isolated rat hepatocytes. Biochem Biophys Res Commun. 1983;115(2):730–6.
Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr. 1982;101(5):782–5.
Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med. 1986;15(4):373–90.
Graf R, Gossrau R, Merker HJ, et al. Enzyme cytochemistry combined with electron microscopy, pharmacokinetics, and clinical chemistry for the evaluation of the effects of steady-state valproic acid concentrations on the mouse. Histochemistry. 1985;83(4):347–58.
Whitin JC, Tham DM, Bhamre S, et al. Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol Genet Metab. 1998;65(3):238–45.
Acknowledgements
All authors have read the policies as outlined by the journal.
Contributors
None.
Funders
None.
Prior Presentation
None.
Conflict of Interest
None Disclosed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patel, S.M., Graff-Radford, J. & Wieland, M.L. Valproate-induced Fanconi Syndrome in a 27-Year-old Woman. J GEN INTERN MED 26, 1072–1074 (2011). https://doi.org/10.1007/s11606-011-1708-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-011-1708-7